

Table of Contents

1.0	Introduction.....	4
2.0	Scope.....	5
3.0	References.....	5
4.0	Definitions and Concepts.....	6
4.1	Clinical investigation	6
4.2	Clinical data	6
4.3	Clinical evaluation	6
4.4	Clinical evidence.....	7

Preface

The document herein was produced by the Global Harmonization Task Force, a voluntary group of representatives from medical device regulatory agencies and the regulated industry. The document is intended to provide non-binding guidance for use in the regulation of medical devices, and has been subject to consultation throughout its development.

There are no restrictions on the reproduction, distribution or use of this document; however, incorporation of this document, in part or in whole, into any other document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the Global Harmonization Task Force.

1.0 Introduction

At its October 2002 meeting, the GHTF Steering Committee adopted the goal that the GHTF would seek to evolve beyond convergence of regulatory requirements to embrace mutual acceptance of common data submissions, pre-market conformity assessment processes, quality systems, quality systems auditing results, and a broad sharing of post-marketing experience. The objective was to allow presentation of data that are acceptable in principle to relevant authorities as the basis for meeting regulatory requirements.

Following preliminary work undertaken by the GHTF Steering Committee's *ad hoc* working group on "common data" and subsequent work by another *ad hoc* working group on "clinical evidence", the Steering Committee asked that a new Study Group for clinical evidence (Study Group 5) be formed. The broad goal for Study Group 5 is to promote the convergence of the regulatory requirements for the generation and presentation of evidence of the clinical safety and performance of medical devices. Study Group 5 recognises that, in order to progress convergence of regulatory requirements and acceptance of common data, it is necessary to have a common understanding and application of terminology, concepts and principles.

It is anticipated that convergence of requirements for clinical evidence, including common data submissions, will lead to better understanding of medical device safety and performance by all stakeholders, more efficient use of resources of the clinical community, medical device regulators and industry, and increased transparency and confidence in the global regulatory model. Ultimately, there should be more efficient, predictable and timely access to safe and effective medical technology by patients and society worldwide.

Clinical evidence and the Essential Principles of safety and performance of medical devices

The GHTF *Essential Principles of Safety and Performance of Medical Devices* (the Essential Principles) set out the requirements relating to the safety and performance of medical devices. Of these, Essential Principles 1, 3, 4 and 6 in particular require that a medical device achieve its intended performance during normal conditions of use and that the known, and foreseeable risks, and any undesirable side-effects, are minimised and acceptable when weighed against the benefits of the intended performance.

The diversity of medical devices and the technologies on which they are based pose special challenges for manufacturers, conformity assessment bodies and regulators alike when trying to identify what should constitute evidence sufficient to demonstrate compliance with the Essential Principles. Some technologies have been available for many years and are well characterised from a clinical safety and performance viewpoint. On the other hand, many devices utilise new, state-of-the-art technology that has had little prior application in the treatment of humans. Furthermore, their intended purpose and clinical application can vary widely with end results influenced by a wide range of different and differently experienced end-users.

Given the complexity of the medical devices milieu, the assessment of what is acceptable clinical evidence for the purpose of demonstrating compliance with the Essential Principles must be undertaken on a case-by-case basis. To this end, it is important to have an understanding of how medical devices are brought to market and of the role that clinical data and its evaluation plays in this process.

2.0 Scope

This document is the first produced by Study Group 5 and is intended to:

- introduce the concepts of clinical evaluation and clinical evidence;
- examine the relationship between clinical investigation, clinical data, clinical evaluation and clinical evidence; and
- serve as guidance to all those involved in the generation, compilation and review of clinical evidence sufficient to support the marketing of medical devices (regulatory authorities, conformity assessment bodies, manufacturers of medical devices and their associated industry groups).

The definitions and concepts contained within this document are intended to apply to the establishment and maintenance of conformity with the relevant Essential Principles for medical devices generally. Specific guidance will be developed in other documents in relation to *in vitro* diagnostic devices. Similarly, guidance about how to generate, compile and present clinical evidence for the purpose of demonstrating compliance with the Essential Principles for safety and performance of a medical device will be addressed in future documents.

3.0 References

GHTF final documents

[SG1/N041:2005 *Essential Principles of Safety and Performance of Medical Devices*](#)

[SG1/N040:2006 *Principles of Conformity Assessment for Medical Devices*](#)

International standards

[ISO 14155-1: 2003 *Clinical investigation of medical devices for human subjects – Part 1 General requirements*](#)

[ISO 14155-2: 2003 *Clinical investigation of medical devices for human subjects – Part 2 Clinical investigation plans*](#)

4.0 Definitions and Concepts

4.1 Clinical investigation

Definition: Any systematic investigation or study in or on one or more human subjects, undertaken to assess the safety and/or performance of a medical device.

Explanation: This term is synonymous with ‘clinical trial’ and ‘clinical study’.

Clinical investigations include feasibility studies and those conducted for the purpose of gaining market approval, as well as investigations conducted following marketing approval.

Routine post market surveillance may not constitute a clinical investigation (e.g. investigation of complaints, individual vigilance reports, literature reviews).

4.2 Clinical data

Definition: Safety and/or performance information that are generated from the clinical use of a medical device.

Explanation: Sources of clinical data may include:

- (i) Results of pre- and postmarket clinical investigation(s) of the device concerned
- (ii) Results of pre- and postmarket clinical investigation(s) or other studies reported in the scientific literature of a justifiably comparable device
- (iii) published and/or unpublished reports on other clinical experience of either the device in question or a justifiably comparable device

4.3 Clinical evaluation

Definition: The assessment and analysis of clinical data pertaining to a medical device to verify the clinical safety and performance of the device when used as intended by the manufacturer.

Explanation: This is a process undertaken by manufacturers of medical devices to help establish compliance with the relevant Essential Principles for safety and performance. The result of this process is a report that can be reviewed by conformity assessment bodies and regulators and which details the extent of available data and its quality and demonstrates how the compliance with the Essential Principles is satisfied by the clinical data. Clinical evaluation is an ongoing process - information about clinical safety and performance (e.g. adverse event reports, results from any further clinical investigations, published literature etc) should be monitored

routinely by the manufacturer once the device is available on the market and the benefits and risks reassessed in light of this additional information.

The inputs for clinical evaluation are primarily clinical data in the form of clinical investigation reports, literature reports/reviews and clinical experience. The data required to establish the initial evidence of compliance with the Essential Principles may vary according to the characteristics of the device, its intended use, the claims made by the manufacturer, the existence and adequacy of warnings and other restrictions, and the extent of experience with its use. A key goal of the clinical evaluation is to establish that any risks associated with the use of the device are acceptable when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety. The clinical evaluation will, therefore, also need to cross-reference risk management documents.

4.4 Clinical evidence

Definition: The clinical data and the clinical evaluation report pertaining to a medical device.

Explanation: Clinical evidence is an important component of the technical documentation of a medical device, which along with other design verification and validation documentation, device description, labelling, risk analysis and manufacturing information, is needed to allow a manufacturer to demonstrate conformity with the Essential Principles. It should be cross-referenced to other relevant parts of the technical documentation that impact on its interpretation.

In accordance with applicable local regulations, clinical evidence, in part or in total, may be submitted to and reviewed by conformity assessment bodies and regulatory authorities. The clinical evidence is used to support the marketing of the device, including any claims made about the clinical safety and performance of the device, and the labelling of the device. Figure 1 shows how the need for clinical evidence drives the processes of data generation and clinical evaluation, which produce clinical data and clinical evidence, respectively.

Clinical evidence should be reviewed and updated throughout the product life cycle by the manufacturer as new information relating to clinical safety and performance is obtained from clinical experience during marketing (e.g. adverse event reports, results from any further clinical investigations, formal post market surveillance studies) of the device in question and/or comparable devices.

Figure 1 Overview of process for data generation and clinical evaluation

